In conclusion, the present study reveals YME1L1‐mediated modulation of mitochondrial energy metabolism, identifies the downregulation of YME1L1 as a contributor to AKI, and illuminates the underlying mechanism that transcriptional factor SREBP1c mediates cisplatin‐induced suppression of YME1L1 via direct combining with its promoter domain. Here, SREBF1 is linked to acute kidney injury.